140 related articles for article (PubMed ID: 34778466)
1. Introduction of Two-Dose Mumps-Containing Vaccine into Routine Immunization Schedule in Quzhou, China, Using Cox-Proportional Hazard Model.
Yin Z; Zheng C; Fang Q; Gong X; Cao G; Li J; Xiang Z; Song W
J Immunol Res; 2021; 2021():5990417. PubMed ID: 34778466
[TBL] [Abstract][Full Text] [Related]
2. Assessing the Changes of Mumps Characteristics with Different Vaccination Strategies Using Surveillance Data: Importance to Introduce the 2-Dose Schedule in Quzhou of China.
Zhou C; Song W; Yin Z; Li S; Gong X; Fang Q; Wang S
J Immunol Res; 2020; 2020():8130760. PubMed ID: 32300606
[TBL] [Abstract][Full Text] [Related]
3. Assessment of mumps-containing vaccine effectiveness by dose during 2006 to 2020 in Quzhou, China.
Yin Z; Wen T; Fang Q; Zheng C; Gong X; Li J; Wang S; Xiang Z
Hum Vaccin Immunother; 2022 Nov; 18(5):2086774. PubMed ID: 35675040
[TBL] [Abstract][Full Text] [Related]
4. Assessment of mumps-containing vaccine effectiveness during an outbreak: Importance to introduce the 2-dose schedule for China.
Ma C; Liu Y; Tang J; Jia H; Qin W; Su Y; Wang H; Hao L
Hum Vaccin Immunother; 2018 Jun; 14(6):1392-1397. PubMed ID: 29377772
[TBL] [Abstract][Full Text] [Related]
5. Assessment of one-dose mumps-containing vaccine effectiveness on wild-type genotype F mumps viruses circulating in mainland China.
Cui A; Zhu Z; Mao N; Si Y; Ma Y; Hu Y; Deng X; Wang L; Zeng L; Zhang Y; Xu W
Vaccine; 2018 Sep; 36(38):5725-5731. PubMed ID: 30122648
[TBL] [Abstract][Full Text] [Related]
6. Loss of protective immunity of two-dose mumps-containing vaccine over time: concerns with the new strategy of the mumps immunization program in China.
Wang D; Nie T; Pan F; Wang Y; Wang J; Qin W
Hum Vaccin Immunother; 2021 Jul; 17(7):2072-2077. PubMed ID: 33545016
[No Abstract] [Full Text] [Related]
7. Outbreak of mumps in a student population with high vaccination coverage in China: time for two-dose vaccination.
Qin W; Wang Y; Yang T; Xu XK; Meng XM; Zhao CJ; Li SY; Xie SY; Li KC; Su H
Hum Vaccin Immunother; 2019; 15(9):2106-2111. PubMed ID: 30779678
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation on the short term effectiveness of two doses mumps-containing vaccine policy in Shandong, China].
Xu Q; Xiong P; Fang XQ; Liu XD; Wang CY; Song LZ; Xu AQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Mar; 52(3):265-270. PubMed ID: 29973005
[No Abstract] [Full Text] [Related]
9. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.
Christenson B; Böttiger M
Vaccine; 1991 May; 9(5):326-9. PubMed ID: 1872016
[TBL] [Abstract][Full Text] [Related]
10. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
11. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
[TBL] [Abstract][Full Text] [Related]
12. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
13. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
[TBL] [Abstract][Full Text] [Related]
14. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
15. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
[TBL] [Abstract][Full Text] [Related]
16. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
17. Mumps disease in Beijing in the era of two-dose vaccination policy, 2005-2016.
Ma R; Lu L; Zhou T; Pan J; Chen M; Pang X
Vaccine; 2018 May; 36(19):2589-2595. PubMed ID: 29653850
[TBL] [Abstract][Full Text] [Related]
18. [Mumps epidemic in vaccinated children in West Switzerland].
Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D
Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835
[TBL] [Abstract][Full Text] [Related]
19. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
[TBL] [Abstract][Full Text] [Related]
20. [Study of mumps immunity after administrating measles-mumps-rubella vaccine among children aged 2-7 years old in Jiangsu Province in 2015].
Liu YB; Hu Y; Deng XY; Wang ZG; Sun X; Lu PS; Guo HX; Tang FY; Zhou MH
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):593-597. PubMed ID: 28693082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
